Enrollment completed for first Phase 3 study of perfluorohexyloctane
January 19, 2021
Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.